01290nas a2200205   4500000000100000008004100001260001300042653001200055653003100067653001100098653001000109653001200119100001400131700001400145245006100159300001100220490000700231520083200238022001401070       1985                            d  c1985 Jun10aDapsone10aDrug Resistance, Microbial10aHumans10aKenya10aleprosy1 aOrege P A1 aOwili D M00aDapsone resistant leprosy, the western Kenya experience.  a139-420 v373 a<p>41 patients out of 804 registered lepromatous (LL) and borderline lepromatous (BL) patients were studied for possible dapsone resistance by series of biopsy specimens, skin smears and clinical examination. These patients were drawn from a pool of 4384 registered leprosy patients in the west Kenya Leprosy Control Project area. Six out of fourty one cases (14.6%) were confirmed as dapsone resistant by series of biopsy specimens taken when patients were on supervised dapsone therapy; 11 patients (26.8%) were suspected to be resistant and 24 patients (58.6%) responded well to dapsone therapy. All the confirmed cases were lepromatous leprosy cases. We therefore found that there is dapsone resistance here with a maximal prevalence rate of 7 per 1000 in all lepromatous cases and 14.6% in clinically suspicious cases.</p>  a0041-3232